Spotlight on General Practice

Credits: 0.25 CME
Rethinking Migraine Treatment: Highlights and Recent Advances
Stewart J. Tepper, MD
Forefront Collaborative

Rethinking Migraine Treatment: Highlights and Recent Advances

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: December 11, 2018
Expires: December 10, 2019
15 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  • Describe major emerging acute and preventive migraine therapies.

Activity Description

Paradigm shift, or shattered? The thinking around both preventive and acute treatment of migraine is amidst a radical change. From a new class of treatment targeting disease-specific pathophysiology to emerging therapies incorporating neuromodulatory devices, Stewart Tepper, MD, gets practicing clinicians up to speed in a Hot Topics Webinar that details the key treatment advances transforming migraine care.

Statement of Educational Need

With the recent approvals of new breakthroughs, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

New Horizons in Headache Treatment
Pathophysiology and Neurotransmitter Targets
New Devices and Medications for Delivering Medications
New Acute Treatment Classes
Prevention: MABs
Neuromodulation for Headache

Faculty

Stewart J. Tepper, MD
Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, Alphasights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management,  Neurolief, Nordic BioTech, Pfizer, Scion Neurostim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Scion Neurostim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva Pharmaceutical Industries.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Planner (Forefront Collaborative): Katie Detzler

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 3 out of 3. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Lily_Zurkovsky@forefrontcollab.com
317.846.2770

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

General Practice Presentations

0.50 CME / CNE
Global Education Group
ADPKD - What Your Patients Want You to Know

ADPKD - What Your Patients Want You to Know

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: December 31, 2018
Expires: December 31, 2019
30 minutes to complete

Jointly Provided By

In Partnership With

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Terms of Offering

This activity was released on 12/31/18 and is valid for one year. Requests for credit must be made no later than 12/31/19.

Target Audience

The educational design of this activity addresses the needs of nephrology and primacy care HCPs involved in the treatment of patients with ADPKD.

Statement of Need/Program Overview

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic inherited progressive condition in which renal cysts develop and expand, eventually leading to severe loss of kidney function. Complications include pain, hypertension, and cardiovascular disease. Unless patients undergo dialysis or transplantation, ADPKD is inevitably fatal. Because it is a genetically transmitted disease, there is a 50/50 chance that each child of a parent with ADPKD will develop the disease. Management of ADPKD has evolved significantly in recent years; in 2018, the first drug indicated for slowing progression of the disease was approved.

ADPKD is considered a rare disease, but with a prevalence of approximately 1:1000, the odds are high that most primary care practices have 1 or more patients with the condition – whether or not it has been diagnosed. Primary care providers would benefit from education that raises their awareness of ADPKD, explains strategies for managing the disease and its complications, and provides them with tools to promote and preserve optimal patient health for as long as possible.

This unique online Clinical Comparison CME/CE activity allows learners to learn about ADPKD, discover evidence-based treatment strategies, apply their learning in a series of interactive real-world challenges, receive feedback on their choices, and compare their choices with those of their peers. The content of the program was developed, in part, through interviews with ADPKD patients and their caregivers, who shared their insights and what they wish their clinicians knew about the disease, its management, and its impact on their lives.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Identify clinical approaches for the early recognition, efficient evaluation, and timely diagnosis of autosomal dominant polycystic kidney disease (ADPKD)
  • Identify data-driven approaches to the comprehensive care of patients with ADPKD
  • Recognize which patients with ADPKD are most likely to benefit from currently available and emerging therapies for ADPKD

Faculty

Brittany P. Cavanaugh, DO
Professor of Internal Medicine
Yale University School of Medicine
New Haven, Connecticut


Neera Dahl, MD
Associate Professor of Nephrology
Yale University School of Medicine
New Haven, Connecticut


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Global Academy for Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time.

System Requirements

PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader

MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Brittany P. Cavanaugh, DO
Nothing to disclose

Neera Dahl, MD
Has been a Consultant/Independent Contractor and a member of the Speakers’ Bureau for Otsuka America Pharmaceutical, Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Tom Garry: Nothing to disclose
Shirley V. Jones, MBA: Nothing to disclose
Mike LoPresti: Nothing to disclose
Ron Schaumburg: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Global Academy for Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Copyright © 2018 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc. and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, the accredited provider or the Publisher will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

0.75 CME
Postgraduate Institute for Medicine
Clinical Reflections®: Reflecting on Errors and Missed Opportunities in Chronic Urticaria

Clinical Reflections®: Reflecting on Errors and Missed Opportunities in Chronic Urticaria

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: February 1, 2019
Expires: January 31, 2020
45 minutes to complete

Jointly Provided By

Postgraduate Institute for Medicine (PIM) in joint providership with RMEI Medical Education (RMEI).

Target Audience

US-based allergy/immunology and dermatology clinicians

Learning Objectives

After engaging in this educational activity, participants will be able to:

  1. Recognize physical exam findings and symptomatology suggestive of chronic urticaria (CU) and appropriately apply evidence-based practices regarding diagnostic testing and laboratory workup
  2. Utilize a guideline-driven approach to treatment intensification for safe and effective management of CU patients in need of second- and third-line treatment options, while taking into account quality of life issues

Activity Description

This unique educational initiative harnesses the power of reflection and recognition of suboptimal approaches to patient care to allow you to rethink clinical decisions based on the scenarios presented, and to modify treatment plans accordingly. You can compare your responses to interactive questions with those of your peers and learn from our expert faculty.

Statement of Educational Need

Urticaria is an inflammatory skin condition characterized by intensely pruritic, erythematous wheals, commonly referred to as “hives,” ranging from several millimeters to several centimeters in diameter.1 Individual wheals characteristically resolve within 24 hours of development without leaving residual skin markings. However, resolving lesions are often concomitantly replaced by new wheals.

Acute urticaria tends to be self-limiting, often resolving within hours to days.2 By contrast, a diagnosis of chronic urticaria (CU), also referred to as chronic idiopathic urticaria (CIU) or chronic spontaneous urticaria (CSU), is made when symptoms last >6 weeks.3 In some cases of CU, symptoms persist continually, while others are episodic with symptoms occurring at varying intervals (hours to weeks).4 Approximately 40% of patients with CU also develop angioedema,5 characterized by rapid swelling of the lower layers of the dermis and the subcutaneous or submucosal tissue of the skin and mucous membranes, most commonly affecting the lips and eyelids, or more rarely, the respiratory or gastrointestinal tracts.6 The point prevalence of CU is estimated at 0.5% to 1%.4

References:
  1. World Allergy Organization. Urticaria and angioedema: synopsis. 2004. www.worldallergy.org/professional/allergic_diseases_center/urticaria/urticariasynopsis.php. Accessed December 21, 2018.
  2. Axelrod S, Davis-Lorton M. Urticaria and angioedema. Mt Sinai J Med. 2011;78(5):784-802.
  3. Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105(4):664-672.
  4. Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37(5):631-650.
  5. Amar SM, Dreskin SC. Urticaria. Prim Care. 2008;35(1):141-157.
  6. Maurer M, Weller K, Bindsley-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317-330.

Faculty

Michael E. Manning, MD, FAAAAI, FACAAI
Michael E. Manning, MD, FAAAAI, FACAAI
President/Medical Director
Medical Research of Arizona
Allergy, Asthma and Immunology Associates, Ltd.
Scottsdale, AZ

Michael E. Manning, MD, FAAAAI, FACAAI, is president of Allergy, Asthma and Immunology Associates, Ltd., and medical director of the clinical research division, Medical Research of Arizona.

Dr Manning is a graduate of Baylor University in Waco, TX and he received his medical degree from the University of Texas Medical School at Houston. He completed an internship and subsequently residency in internal medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ, and an allergy and immunology fellowship at Scripps Clinic and Research Foundation in La Jolla, CA.

Dr Manning has served as president of the Greater Phoenix Allergy Society, the Arizona State Allergy and Asthma Society, and the Western Society of Allergy, Asthma and Immunology. He is a fellow of the American College of Allergy, Asthma and Immunology and American Academy of Allergy, Asthma and Immunology. Dr Manning is currently on the Board of Regents of the American College of Allergy, Asthma and Immunology.

Michael E. Manning, MD, FAAAAI, FACAAI, has affiliations with CSL Behring, DBV Technologies, Pharming, Shire (Consulting Fees); AstraZeneca, CSL Behring, Genentech, Pharming, Shire (Speakers Bureaus); Aimmune, BioCryst, CSL Behring, Genentech/Novartis, GSK, Hoffmann-La Roach, Merck, Sanofi, Shire/Dyax (Contracted Research).



Anne Marie Ditto, MD 
Associate Professor of Medicine
Division of Allergy-Immunology 
Northwestern University
Feinberg School of Medicine 
Chicago, IL 

Anne Marie Ditto, MD, is an associate professor of medicine in the division of Allergy-Immunology at Northwestern University Feinberg School of Medicine in Chicago, IL. She earned her medical degree at the University of Illinois at Chicago. Her internship, residency, and fellowship were all completed at Northwestern University. Dr Ditto is board certified in allergy-immunology.

Dr Ditto is a practicing allergist with a special interest in urticaria, eosinophilic esophagitis, asthma, and idiopathic anaphylaxis. She volunteers monthly at the Community Health Clinic where she founded an asthma/allergy clinic. She is also actively involved in the allergy-immunology training program at Northwestern, where she has trained over 75 allergists and teaches students and residents in outpatient clinics.

Dr Ditto was invited to fellowship in the American College of Physicians (ACP) and Royal Society of Medicine (RSM) and her distinguished teaching and volunteer work has been recognized through numerous awards, including the Northwestern Medical Faculty Foundation “Center of Excellence Award” for Community Service and Community Health’s “Volunteer Specialist of the Year.

Dr Ditto is a former president of the Illinois Society of Allergy, Asthma and Immunology and currently serves as Governor of the Midwest Region of the American Academy of Allergy, Asthma and Immunology’s Federation of Regional State and Local Allergy, Asthma and Immunology Societies (RSLAAIS) and also serves as vice-chair of the AAAAI anaphylaxis committee. She has published numerous articles and book chapters in the field of allergy- immunology and recently edited the “Anaphylaxis” issue of Immunology and Allergy Clinics of North America.

Anne Marie Ditto, MD, has no affiliations with commercial interests to disclose.



Luz Fonacier, MD, FAAAAI, FACAAI
Professor of Medicine
State University of New York at Stony Brook
Stony Brook, NY
Head of Allergy
Program Director, Allergy and Immunology
Fellowship Program
NYU Winthrop Hospital
Mineola, NY 

Luz Fonacier, MD, FAAAAI, FACAAI, is the head of allergy in NYU Winthrop Hospital, a clinical campus of Stony Brook University School of Medicine and serves as the program director for the Allergy and Immunology Fellowship Program. Dr Fonacier is also a professor of medicine in USNY at Stony Brook. She completed residencies in dermatology and internal medicine, a fellowship in allergy and immunology in New York Hospital-Cornell Medical Center, and a fellowship in dermal immunology at New York University Medical Center.

Dr Fonacier serves as the Treasurer of the American College of Allergy, Asthma and Immunology (ACAAI). She chaired the Committee on Dermatologic Allery of the ACAAI and the Food Allergy, Dermatologic, Drug and Anaphylaxis Interest Section of the American Academy of Allergy, Asthma and Immunology (AAAAI). She is the recipient of the ARTrust™  and Anjuli Seth Nayak AAAAI Lectureship, the ACAAI John P. McGovern Lectureship, the ACAAI Jean A. Chapman Memorial Lectureship, the ACAAI “Women in Allergy Award”, and the Presidential Award of Asian Pacific Association of Allergy and Clinical Immunology. Dr Fonacier also served as president of the Long Island Allergy Society.

Dr Fonacier has numerous publications in textbooks and journals and continues to be a speaker and faculty in the annual national conventions of ACAAI, AAAAI, and other national and international societies. Because of her training in dermatology, allergy, and immunology, Dr Fonacier’s special interest is the dermatologic manifestations of allergic diseases.

Luz Fonacier, MD, FAAAAI, FACAAI, has affiliations with Regeneron (Consulting Fees); Regeneron (Speakers Bureaus); Pfizer, Regeneron, Shire (Contracted Research).



Conflict of Interest Policy/Disclosure Statement

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

Complete the evaluation form and participants will be entered into a drawing to win a $100 Amazon Gift Card!

*The expense for this gift card is solely funded by RMEI Medical Education. No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.00 CME
Global Education Group
Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis: Looking Beyond Barriers to Optimize Therapy

Evolving Management Strategies for Moderate-to-Severe Atopic Dermatitis: Looking Beyond Barriers to Optimize Therapy

Start
Free CME
1.0 AMA PRA Category 1 Credit
Released: December 14, 2018
Expires: December 13, 2019
60 minutes to complete

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with atopic dermatitis.

Statement of Need

Atopic dermatitis is a common, chronic inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of atopic dermatitis can have a substantial effect on patients’ quality of life, particularly in those with moderate-to-severe disease.3,4 A better understanding of atopic dermatitis etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now available to treat patients with moderate-to-severe disease, and several other therapies are in late-stage clinical development.7-10 With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, dermatologists will benefit from updates on the latest clinical trial data and practical recommendations on how to translate those results into daily clinical decision-making. In this Evidence-Based Best Practices™ program, internationally recognized experts will review the latest published evidence with a goal of providing recommendations to enhance overall patient outcomes. The expert faculty panel will discuss the pathophysiologic underpinnings of atopic dermatitis, share best practices related to comprehensive patient evaluations, and relay their own clinical experience in managing patients with moderate-to-severe disease.

References

  • Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
  • Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
  • Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7. [Epub ahead of print].
  • Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
  • Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
  • Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  • Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  • de Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083-1101.
  • Boguniewicz M. Biologic therapy for atopic dermatitis: moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 2017;5(6):1477-1487.
  • Cotter DG, et al. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3S1):S53-S62.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss atopic dermatitis pathophysiology, including clinically relevant molecular and cellular targets
  • Assess patients with atopic dermatitis longitudinally for uncontrolled symptoms, disease flares, comorbidities, and clinical responses to their current treatment regimens
  • Describe the clinical profiles of targeted biologic therapies for the treatment of moderate-to-severe atopic dermatitis
  • Optimize treatment regimens for patients with moderate-to-severe atopic dermatitis to reduce symptomatology, address comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
  • Educate patients and caregivers to improve their understanding of atopic dermatitis to promote shared decision-making and treatment adherence

Faculty

Marjolein de Bruin-Weller, MD, PhD
Head, National Expertise Center for Atopic Dermatitis
Department of Dermatology/Allergology
University Medical Center Utrecht
Utrecht, The Netherlands



Eric L. Simpson, MD, MCR
Professor of Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, Oregon, USA



Andreas Wollenberg, MD, PhD
Professor
Department of Dermatology and Allergy
Ludwig-Maximilian University of Munich
Munich, Germany


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 70% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Marjolein de Bruin-Weller, MD, PhD

  • Consultant/Advisor: AbbVie Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme
  • Grant/Research Support: Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.

Eric L. Simpson, MD, MCR

  • Consultant/Advisor: AbbVie Inc., Eli Lilly and Company, Galderma Laboratories, L.P., LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme.
  • Grant/Research Support: Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc.

Andreas Wollenberg, MD, PhD

  • Consultant/Advisor: Almirall Limited, Beiersdorf AG, Galderma S.A., LEO Pharma Inc., L’Oréal S.A., MedImmune, LLC, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.
  • Grant/Research Support: Beiersdorf AG, LEO Pharma Inc.
  • Speakers Bureau: Almirall Limited, Anacor Pharmaceuticals, Inc., Astellas Pharma Europe Ltd, Beierdsorf AG, Bioderma Laboratoire Dermatologique, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Galderma S.A., Hans Karrer GMBH, LEO Pharma Inc., L’Oréal S.A., Meda AB, MedImmune, LLC, Merck Sharp & Dohme Corp., Novartis Pharma AG, Pierre Fabre Laboratories, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi-Aventis Europe S.A.S.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Stacey Ullman, MHS
Nothing to disclose

Ashley Marostica, RN, MSN
Nothing to disclose

Lindsay Borvansky
Nothing to disclose

Andrea Funk
Nothing to disclose

Liddy Knight
Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
Forefront Collaborative
Rethinking Migraine Treatment: Highlights and Recent Advances

Rethinking Migraine Treatment: Highlights and Recent Advances

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: December 11, 2018
Expires: December 10, 2019
15 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  • Describe major emerging acute and preventive migraine therapies.

Activity Description

Paradigm shift, or shattered? The thinking around both preventive and acute treatment of migraine is amidst a radical change. From a new class of treatment targeting disease-specific pathophysiology to emerging therapies incorporating neuromodulatory devices, Stewart Tepper, MD, gets practicing clinicians up to speed in a Hot Topics Webinar that details the key treatment advances transforming migraine care.

Statement of Educational Need

With the recent approvals of new breakthroughs, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

New Horizons in Headache Treatment
Pathophysiology and Neurotransmitter Targets
New Devices and Medications for Delivering Medications
New Acute Treatment Classes
Prevention: MABs
Neuromodulation for Headache

Faculty

Stewart J. Tepper, MD
Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, Alphasights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management,  Neurolief, Nordic BioTech, Pfizer, Scion Neurostim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Scion Neurostim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva Pharmaceutical Industries.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Planner (Forefront Collaborative): Katie Detzler

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 3 out of 3. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Lily_Zurkovsky@forefrontcollab.com
317.846.2770

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
Vindico
Advances in the Treatment of Peanut Allergy: Rapid Response from Seattle

Advances in the Treatment of Peanut Allergy: Rapid Response from Seattle

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: November 30, 2018
Expires: November 30, 2019
0.75 hours to complete

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Faculty

Activity Chair:
J. Andrew Bird, MD
J. Andrew Bird, MD
Associate Professor of Pediatrics
Division of Allergy and Immunology
University of Texas Southwestern Medical Center
Director, Food Allergy Center
Children’s Medical Center of Dallas
Dallas, TX

Disclosure: Consulting Fee: Aimmune, DBV Technologies, Pharm-Olam
Non-CME Services Fees: Aimmune, DBV Technologies
Contracted Research: Aimmune, DBV Technologies


Faculty:
Ruchi S. Gupta, MD, MPH
Ruchi S. Gupta, MD, MPH
Professor of Pediatrics and Medicine
Northwestern Feinberg School of Medicine
Director
Science and Outcomes of Allergy and Asthma Research Team
Clinical Attending
Ann and Robert H. Lurie Children's Hospital Chicago
Chicago, IL

Disclosure: Consulting Fee: Aimmune, BEFORE Brands, DBV Technologies, Kaleo Pharma
Contracted Research: Thermo Fisher Scientific, United Health Group


Edwin H. Kim, MD, MS
Edwin H. Kim, MD, MS
Director, UNC Food Allergy Initiative
University of North Carolina at Chapel Hill
Chapel Hill, NC

Disclosure: Consulting Fee: Aimmune, DBV Technologies
Contracted Research: Aimmune, Astellas, DBV Technologies, FARE, HAL Allergy
Research Support: Wallace Foundation


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.


Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.


Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Activity Description

The prevalence of peanut allergy in adults and children continues to increase, significantly disrupting the lives of the millions of affected individuals as well as their families. Although no therapies have been approved for the treatment of peanut allergies, several are currently being evaluated in clinical studies, providing the potential for safe and effective therapeutic options. Within this Rapid Response from Seattle, experts in the field examine the prevalence and burden of IgE-mediated food allergy with a focus on peanut allergy, assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy, and evaluate the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Examine the prevalence and burden of IgE-mediated food allergy, with a focus on peanut allergy.
  • Assess the latest clinical data regarding the use of oral immunotherapy for the treatment of patients with peanut allergy.
  • Examine the challenges associated with heterogeneity in terminology used in immunotherapy clinical trials for the management of patients with peanut allergy.

Target Audience

The intended audience for the activity is allergists, immunologists and other health care professionals involved in the treatment of patients with food allergies, particularly peanut allergy.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s) Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Aimmune Therapeutics.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

0.75 CME
Integrity Continuing Education, Inc.
Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Improving Severe Asthma Control through Comprehensive Patient Assessment and Tailored Treatment Selection

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: November 20, 2018
Expires: November 20, 2019
1 hour to complete

Provided by


Integrity Continuing Education, Inc.

Target Audience

This educational initiative has been designed for allergists, pulmonologists, and otolaryngic allergists involved in the management of patients with severe asthma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe clinical criteria for severe asthma and outline an approach to assessing symptom control and disease burden
  • Identify known phenotypes of severe asthma
  • Develop an approach to the treatment of severe asthma that is personalized to the individual patient and describe the most recent clinical data on new and emerging therapies for severe asthma
  • Identify strategies for improving communication to promote collaborative decision-making and the ability to self-manage among patients with severe asthma

Activity Description

Despite recent advances in our understanding of the pathophysiology of asthma and a corresponding expansion of targeted treatment modalities, severe asthma care continues to be a challenge in clinical practice. This program is designed to address this issue by imparting clinical knowledge and competence to clinicians that will promote comprehensive assessment and highly personalized treatment of patients whose symptoms meet the criteria for severe asthma. In addition, this initiative is also targeted at providing clinicians with guidance on strategies for improving disease awareness, increasing collaborative decision-making, and promoting self-management among patients with severe asthma.

Faculty

William W. Busse, MD
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
School of Medicine and Public Health
University of Wisconsin
Madison, Wisconsin


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

William W. Busse, MD
Royalty: Elsevier
Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Genzyme and Regeneron Pharmaceuticals, Teva Pharmaceuticals
Data Monitoring Boards/Study Oversight Committees: Boston Scientific, Genentech, ICON Clinical Research Ltd.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of November 20, 2018 through November 20, 2019 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.